Mucopolysaccharidosis I: Management and treatment guidelines

Pediatrics

Volumn 123, Issue 1, 2009, Pages 19-29

  Muenzer, Joseph ^a,d   Wraith, James E ^b   Clarke, Lorne A ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

l iduronidase; Biochemical genetics; Enzyme replacement therapy; Guidelines; Hematopoietic stem cell transplantation; Lysosomal storage disorder; Mucopolysaccharidosis

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; GLYCOSAMINOGLYCAN; LARONIDASE; PLACEBO;

ABDOMINAL PAIN; ANESTHESIA; ARTHROPATHY; ARTICLE; ASSAULT; BACTERIAL ENDOCARDITIS; BLINDNESS; BLOOD BRAIN BARRIER; CARDIOMYOPATHY; CARPAL TUNNEL SYNDROME; CLINICAL TRIAL; COGNITIVE DEVELOPMENT; CONGESTIVE HEART FAILURE; COR PULMONALE; CORNEA TRANSPLANTATION; CORONARY ARTERY DISEASE; DISEASE COURSE; EAR INFECTION; ENZYME REPLACEMENT; FEVER; FLUSHING; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL TRACT FUNCTION; GINGIVA DISEASE; HEADACHE; HEARING; HEARING LOSS; HEART ARRHYTHMIA; HEART FUNCTION TEST; HEART VALVE REPLACEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERNIA; HUMAN; HURLER SYNDROME; HYPERTENSION; INCIDENCE; KYPHOSIS; MUSCULOSKELETAL FUNCTION; NEUROLOGIC EXAMINATION; NONHUMAN; OBSTRUCTIVE AIRWAY DISEASE; OPEN ANGLE GLAUCOMA; PALLIATIVE THERAPY; PHENOTYPE; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; RASH; RESPIRATORY TRACT DISEASE; RHINITIS; SCOLIOSIS; SIDE EFFECT; SINUSITIS; SNORING; URINALYSIS; VALVULAR HEART DISEASE; DISEASE MANAGEMENT; INTERNATIONAL COOPERATION; TREATMENT OUTCOME;

DISEASE MANAGEMENT; HUMANS; INTERNATIONALITY; MUCOPOLYSACCHARIDOSIS I; TREATMENT OUTCOME;

EID: 59449100963     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-0416     Document Type: Article

References (67)

1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver C, Beaudet A, Sly W, et al, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw Hill; 2001:3421-3452
2. Hopkin RJ, Grabowski GA. Lysosomal storage diseases. In: Fauci A, Kasper D, Braunwald E, et al, eds. Harrison's Principles of Internal Medicine. 17th ed. New York, NY: McGraw Hill; 2005: 2452-2456
3. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249-254
4. Scott HS, Bunge S, Gal A, Clarke LA, Morris CP, Hopwood JJ. Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications. Hum Mutat. 1995;6(4):288-302
5. Bunge S, Clements PR, Byers S, Kleijer WJ, Brooks DA, Hop- wood JJ. Genotype-phenotype correlations in mucopolysaccharidosis type I using enzyme kinetics, immunoquantification and in vitro turnover studies. Biochim Biophys Acta. 1998; 1407(3):249-256
6. Hopwood JJ, Muller V. Biochemical discrimination of Hurler and Scheie syndromes. Clin Sci (Lond). 1979;57(3):265-272
7. Beesley C, Meaney C, Greenland G, et al. Mutational analysis of 85 mucopolysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutations. Hum Genet. 2001; 109(5):503-511
8. Terlato NJ, Cox GF. Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature. Genet Med. 2003;5(4): 286-294
9. Yogalingam G, Guo XH, Muller VJ, et al. Identification and molecular characterization of α-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy. Hum Mutat. 2004;24(3):199-207
10. Stenson PD, Ball EV, Mort M, et al. Human Gene Mutation Database: 2003 update. Hum Mutat. 2003;21(6):577-581
11. Scott HS, Nelson PV, Litjens T, Hopwood JJ, Morris CP. Multiple polymorphisms within the α-L-iduronidase gene (IDUA): implications for a role in modification of MPS-I disease phe- notype. Hum Mol Genet. 1993;2(9):1471-1473
12. Vijay S, Wraith JE. Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I. Acta Paediatr. 2005;94(7):872-877
13. Pastores G, Arn P, Beck M, et al. The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with mucopolysaccharidosis type I. Mol GenetMetab. 2007;91(1):37-47
14. Hall CW, Liebaers I, Di Natale P, Neufeld EF. Enzymatic diagnosis of the genetic mucopolysaccharide storage disorders. Methods Enzymol. 1978;50:439-456
15. Chamoles NA, Blanco MB, Gaggioli D, Casentini C. Hurler-like phenotype: enzymatic diagnosis in dried blood spots on filter paper. Clin Chem. 2001;47(12):2098-2102
16. Aronovich EL, Pan D, Whitley CB. Molecular genetic defect underlying α-L-iduronidase pseudodeficiency. Am J Hum Genet. 1996;58(1):75-85
17. Wraith JE. The mucopolysaccharidoses: a clinical review and guide to management. Arch Dis Child. 1995;72(3):263-267
18. Khan S, Sehat K, Calthorpe D. Cervical cord compression in an elderly patient with Hurler's syndrome: a case report. Spine. 2003;28(16):E313-E315
19. Boor R, Miebach E, Bruhl K, Beck M. Abnormal somatosensory evoked potentials indicate compressive cervical myelopathy in mucopolysaccharidoses. Neuropediatrics. 2000;31(3):122-127
20. Van Heest AE, House J, Krivit W, Walker K. Surgical treatment of carpal tunnel syndrome and trigger digits in children with mucopolysaccharide storage disorders. J Hand Surg [Am]. 1998; 23(2):236-243
21. Wraith JE, Alani SM. Carpal tunnel syndrome in the mucopolysaccharidoses and related disorders. Arch Dis Child. 1990; 65(9):962-963
22. Ashworth JL, Biswas S, Wraith E, Lloyd IC. The ocular features of the mucopolysaccharidoses. Eye. 2006;20(5):553-563
23. Ashworth JL, Biswas S, Wraith E, Lloyd IC. Mucopolysaccharidoses and the eye. Surv Ophthalmol. 2006;51(1):1-17
24. Leighton SE, Papsin B, Vellodi A, Dinwiddie R, Lane R. Disordered breathing during sleep in patients with mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol. 2001;58(2):127-138
25. Santamaria F, Andreucci MV, Parenti G, et al. Upper airway obstructive disease in mucopolysaccharidoses: polysomnography, computed tomography and nasal endoscopy findings. J Inherit Metab Dis. 2007;30(5):743-749
26. Wraith JE. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother. 2005;6(3):489-506
27. Renteria VG, Ferrans VJ, Roberts WC. The heart in the Hurler syndrome: gross, histologic and ultrastructural observations in five necropsy cases. Am J Cardiol. 1976;38(4):487-501
28. Fischer TA, Lehr HA, Nixdorff U, Meyer J. Combined aortic and mitral stenosis in mucopolysaccharidosis type I-S (Ullrich-Scheie syndrome). Heart. 1999;81(1):97-99
29. Minakata K, Konishi Y, Matsumoto M, Miwa S. Surgical treatment for Scheie's syndrome (mucopolysaccharidosis type I-S): report of two cases. Jpn Circ J. 1998;62(9):700-703
30. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116(15):1736 -1754
31. Shinhar SY, Zablocki H, Madgy DN. Airway management in mucopolysaccharide storage disorders. Arch Otolaryngol Head Neck Surg. 2004;130(2):233-237
32. Brain AI. The laryngeal mask: a new concept in airway management. Br J Anaesth. 1983;55(8):801-805
33. Hinek A, Wilson SE. Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. Am J Pathol. 2000;156(3):925-938
34. Whitley CB, Belani KG, Chang PN, et al. Long-term outcome of Hurler syndrome following bone marrow transplantation. Am J Med Genet. 1993;46(2):209-218
35. Guffon N, Souillet G, Maire I, Straczek J, Guibaud P. Follow-up of nine patients with Hurler syndrome after bone marrow transplantation. J Pediatr. 1998;133(1):119-125
36. Peters C, Shapiro EG, Anderson J, et al. Hurler syndrome, part II: outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. Blood. 1998;91(7):2601-2608
37. Vellodi A, Young E, Cooper A, Lidchi V, Winchester B, Wraith JE. Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis. 1999;22(5):638-648
38. Peters C, Steward CG. Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant. 2003;31(4):229-239
39. Souillet G, Guffon N, Maire I, et al. Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant. 2003;31(12):1105-1117
40. Staba SL, Escolar ML, Poe M, et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med. 2004;350(19):1960-1969
41. Grigull L, Beilken A, Schrappe M, et al. Transplantation of allogeneic CD34-selected stem cells after fludarabine-based conditioning regimen for children with mucopolysaccharidosis 1H (M. Hurler). Bone Marrow Transplant. 2005;35(3):265-269
42. Hobbs JR, Hugh-Jones K, Barrett AJ, et al. Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet. 1981;2(8249):709-712
43. Krivit W, Peters C, Shapiro EG. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglu-cosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr Opin Neurol. 1999;12(2):167-176
44. Peters C, Shapiro EG, KrivitW. Hurler syndrome: past, present, and future. J Pediatr. 1998;133(1):7-9
45. Boelens JJ, Wynn RF, O'Meara A, et al. Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant. 2007;40(3):225-233
46. Peters C. Hematopoietic cell transplantation for storage diseases. In: Blume KG, Forman SJ, Appelbaum FR, eds. Hematopoietic Stem Cell Transplantation. Malden, MA: Blackwell Science; 2004:1455-1470
47. Krivit W, Lockman LA, Watkins PA, Hirsch J, Shapiro EG. The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome. J Inherit Metab Dis. 1995;18(4):398-412
48. Malone BN, Whitley CB, Duvall AJ, et al. Resolution of obstructive sleep apnea in Hurler syndrome after bone marrow transplantation. Int J Pediatr Otorhinolaryngol. 1988;15(1): 23-31
49. Braunlin EA, Rose AG, Hopwood JJ, Candel RD, Krivit W. Coronary artery patency following long-term successful engraftment 14 years after bone marrow transplantation in the Hurler syndrome. Am J Cardiol. 2001;88(9):1075-1077
50. Braunlin EA, Stauffer NR, Peters CH, et al. Usefulness of bone marrow transplantation in the Hurler syndrome. Am J Cardiol. 2003;92(7):882-886
51. Weisstein JS, Delgado E, Steinbach LS, Hart K, Packman S. Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation. J Pediatr Orthop. 2004;24(1):97-101
52. Hite SH, Peters C, Krivit W. Correction of odontoid dysplasia following bone-marrow transplantation and engraftment (in Hurler syndrome MPS 1H). Pediatr Radiol. 2000;30(7):464-470
53. Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001;344(3):182-188
54. Sifuentes M, Doroshow R, Hoft R, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab. 2007;90(2):171-180
55. Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double- blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase). J Pediatr. 2004;144(5):581-588
56. Wraith JE, Beck M, Lane R, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human α-L-iduronidase (laronidase). Pediatrics. 2007;120(1). Available at: www.pediatrics.org/cgi/content/ full/120/1/e37
57. Giugliani R, Muíioz Rojas V, Martins AM, et al. A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I. Mol Genet Metab. 2008; In press
58. Kakkis E, McEntee M, Schmidtchen A, et al. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem Mol Med. 1996; 58(2):156-167
59. Shull RM, Kakkis ED, McEntee MF, Kania SA, Jonas AJ, Neufeld EF. Enzyme replacement in a canine model of Hurler syndrome. Proc Natl Acad SciUSA.1994;91(26):12937-12941
60. Braunlin EA, Berry JM, Whitley CB. Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I. Am J Cardiol. 2006;98(3):416-418
61. Pitz S, Ogun O, Bajbouj M, ArashL, Schulze-Frenking G, Beck M. Ocular changes in patients with mucopolysaccharidosis I receiving enzyme replacement therapy: a 4-year experience. Arch Ophthalmol. 2007;125(10):1353-1356
62. Grewal SS, Wynn R, Abdenur JE, et al. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med. 2005;7(2):143-146
63. Cox-Brinkman J, Boelens JJ, Wraith JE, et al. Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome. Bone Marrow Transplant. 2006;38(1):17-21
64. Soni S, Hente M, Breslin N, et al. Pre-stem cell transplantation enzyme replacement therapy in Hurler syndrome does not lead to significant antibody formation or delayed recovery of the endogenous enzyme post-transplant: a case report. Pediatr Transplant. 2007;11(5):563-567
65. Hirth A, Berg A, Greve G. Successful treatment of severe heart failure in an infant with Hurler syndrome. J Inherit Metab Dis. 2007;30(5):820
66. Tolar J, Grewal SS, Bjoraker KJ, et al. Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome. Bone Marrow Transplant. 2008; 41(6):531-535
67. Wynn RF, Mercer J, Page J, Carr TF, Jones S, Wraith JE. Use of enzyme replacement therapy (laronidase) before hematopoi- etic skin cell transplantation for mucopolysaccharidosis I: experience in 18 patients. J Pediatr. 2008; In press